Product Name :
DUPA(OtBu)-OH
Description:
DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.
CAS:
1026987-94-9
Molecular Weight:
488.57
Formula:
C23H40N2O9
Chemical Name:
(4S)-4-({[(2S)-1,5-bis(tert-butoxy)-1,5-dioxopentan-2-yl]carbamoyl}amino)-5-(tert-butoxy)-5-oxopentanoic acid
Smiles :
CC(C)(C)OC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C
InChiKey:
KBDDHSXZOLZZGF-GJZGRUSLSA-N
InChi :
InChI=1S/C23H40N2O9/c1-21(2,3)32-17(28)13-11-15(19(30)34-23(7,8)9)25-20(31)24-14(10-12-16(26)27)18(29)33-22(4,5)6/h14-15H,10-13H2,1-9H3,(H,26,27)(H2,24,25,31)/t14-,15-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
DUPA(OtBu)-OH is a DUPA precursor.{{SKI II} medchemexpress|{SKI II} Immunology/Inflammation|{SKI II} Purity & Documentation|{SKI II} Purity|{SKI II} custom synthesis|{SKI II} Epigenetic Reader Domain} DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.{{VAL-083} web|{VAL-083} Cell Cycle/DNA Damage|{VAL-083} Technical Information|{VAL-083} Data Sheet|{VAL-083} manufacturer|{VAL-083} Epigenetics} |Product information|CAS Number: 1026987-94-9|Molecular Weight: 488.PMID:25023702 57|Formula: C23H40N2O9|Chemical Name: (4S)-4-({[(2S)-1,5-bis(tert-butoxy)-1,5-dioxopentan-2-yl]carbamoyl}amino)-5-(tert-butoxy)-5-oxopentanoic acid|Smiles: CC(C)(C)OC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C|InChiKey: KBDDHSXZOLZZGF-GJZGRUSLSA-N|InChi: InChI=1S/C23H40N2O9/c1-21(2,3)32-17(28)13-11-15(19(30)34-23(7,8)9)25-20(31)24-14(10-12-16(26)27)18(29)33-22(4,5)6/h14-15H,10-13H2,1-9H3,(H,26,27)(H2,24,25,31)/t14-,15-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 125 mg/mL (255.85 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|DUPA(OtBu)-OH (DUPA precursor 17) is a 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA) reagent. The targeting ligand DUPA enhances the transport capability and selectivity of Paclitaxel (PTX) to tumor cells via prostate-specific membrane antigen (PSMA) mediated endocytosis. Besides, DUPA is conjugated with PTX via a disulfide bond, which facilitates the rapid and differential drug release in tumor cells.|In Vivo:|DUPA-targeted Docetaxel (DTX) conjugate with longer spacer has no toxicity in major organs of treated mice.|Products are for research use only. Not for human use.|
